

10731707 8/12/06

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1626KAS

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 FEB 27 New STN AnaVist pricing effective March 1, 2006
NEWS 4 APR 04 STN AnaVist \$500 visualization usage credit offered
NEWS 5 MAY 10 CA/Capplus enhanced with 1900-1906 U.S. patent records
NEWS 6 MAY 11 KOREAPAT updates resume
NEWS 7 MAY 19 Derwent World Patents Index to be reloaded and enhanced
NEWS 8 MAY 30 IPC 8 Rolled-up Core codes added to CA/Capplus and
USPATFULL/USPAT2
NEWS 9 MAY 30 The F-Term thesaurus is now available in CA/Capplus
NEWS 10 JUN 02 The first reclassification of IPC codes now complete in
INPADOC
NEWS 11 JUN 26 TULSA/TULSA2 reloaded and enhanced with new search and
and display fields
NEWS 12 JUN 28 Price changes in full-text patent databases EPFULL and PCTFULL
NEWS 13 JUL 07 Coverage of Research Disclosure reinstated in DWPI
NEWS 14 JUL 11 CHEMSAFE reloaded and enhanced
NEWS 15 JUL 14 FSTA enhanced with Japanese patents

NEWS EXPRESS JUNE 30 CURRENT WINDOWS VERSION IS V8.01b, CURRENT
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8
NEWS X25 X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 15:14:53 ON 18 JUL 2006

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

10731707 8/12/06

	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 15:15:17 ON 18 JUL 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 17 JUL 2006 HIGHEST RN 893880-40-5
DICTIONARY FILE UPDATES: 17 JUL 2006 HIGHEST RN 893880-40-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.



REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10731707.str

10731707 8/12/06



chain nodes :
6 7 8 9 10 11 12 13 14 16 17
ring nodes :
1 2 3 4 5
chain bonds :
1-16 4-6 6-7 6-8 7-12 8-9 9-10 9-11 10-14 12-13 16-17
ring bonds :
1-2 1-5 2-3 3-4 4-5
exact/norm bonds :
1-2 1-5 1-16 2-3 3-4 4-5 4-6 6-7 6-8 7-12 8-9 9-10 9-11 10-14 12-13
16-17
isolated ring systems :
containing 1 :

G1:C,N


Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 8:CLASS 9:CLASS
10:CLASS 11:CLASS 12:CLASS 13:Atom 14:CLASS 16:CLASS 17:CLASS

L1 STRUCTURE UPLOADED

=> d

10731707 8/12/06

L1 HAS NO ANSWERS
L1 STR



G1 C,N

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 15:15:53 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 9 TO ITERATE

100.0% PROCESSED 9 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 9 TO 360
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 15:16:06 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 244 TO ITERATE



100.0% PROCESSED 244 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

L3 0 SEA SSS FUL L1

=>

Uploading C:\Program Files\Stnexp\Queries\107317071.str

10731707 8/12/06



chain nodes :
6 7 8 9 10 11 12 13 14
ring nodes :
1 2 3 4 5
chain bonds :
4-6 6-7 6-8 7-12 8-9 9-10 9-11 10-14 12-13
ring bonds :
1-2 1-5 2-3 3-4 4-5
exact/norm bonds :
1-2 1-5 2-3 3-4 4-5 4-6 6-7 6-8 7-12 8-9 9-10 9-11 10-14 12-13
isolated ring systems :
containing 1 :


G1:C,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 8:CLASS 9:CLASS
10:CLASS 11:CLASS 12:CLASS 13:Atom 14:CLASS

L4 STRUCTURE UPLOADED

10731707 8/12/06

=> d
L4 HAS NO ANSWERS
L4 STR



G1 C,N

Structure attributes must be viewed using STN Express query preparation.

=> s l4
SAMPLE SEARCH INITIATED 15:17:33 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 11 TO ITERATE

100.0% PROCESSED 11 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 22 TO 418
PROJECTED ANSWERS: 0 TO 0

L5 0 SEA SSS SAM L4



=> s l4 full
FULL SEARCH INITIATED 15:17:47 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 260 TO ITERATE

100.0% PROCESSED 260 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

L6 0 SEA SSS FUL L4

=>
Uploading C:\Program Files\Stnexp\Queries\107317072.str

10731707 8/12/06



chain nodes :
6 7 8 9 10 11 12 13
ring nodes :
1 2 3 4 5
chain bonds :
4-6 6-7 6-8 7-11 8-9 9-10 10-13 11-12
ring bonds :
1-2 1-5 2-3 3-4 4-5
exact/norm bonds :
1-2 1-5 2-3 3-4 4-5 4-6 6-7 6-8 7-11 8-9 9-10 10-13 11-12
isolated ring systems :
containing 1 :


G1:C,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 8:CLASS 9:CLASS
10:CLASS 11:CLASS 12:Atom 13:CLASS

L7 STRUCTURE UPLOADED

10731707 8/12/06

=> d
L7 HAS NO ANSWERS
L7 STR



G1 C,N

Structure attributes must be viewed using STN Express query preparation.

=> s 17
SAMPLE SEARCH INITIATED 15:19:52 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 11 TO ITERATE



100.0% PROCESSED 11 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 22 TO 418
PROJECTED ANSWERS: 0 TO 0

L8 0 SEA SSS SAM L7

=>
Uploading C:\Program Files\Stnexp\Queries\107317073.str

10731707 8/12/06



chain nodes :
6 7 8 9 10 11 12
ring nodes :
1 2 3 4 5
chain bonds :
4-6 6-7 6-8 7-11 8-9 9-10 11-12
ring bonds :
1-2 1-5 2-3 3-4 4-5
exact/norm bonds :
1-2 1-5 2-3 3-4 4-5 4-6 6-7 6-8 7-11 8-9 9-10 11-12
isolated ring systems :
containing 1 :

G1:C,N


Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 8:CLASS 9:CLASS
10:CLASS 11:CLASS 12:Atom

L9 STRUCTURE UPLOADED

10731707 8/12/06

=> d
L9 HAS NO ANSWERS
L9 STR



G1 C,N

Structure attributes must be viewed using STN Express query preparation.

=> s 19
SAMPLE SEARCH INITIATED 15:21:04 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 22 TO ITERATE

100.0% PROCESSED 22 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 159 TO 721
PROJECTED ANSWERS: 0 TO 0

L10 0 SEA SSS SAM L9



=> s 19 full
FULL SEARCH INITIATED 15:21:14 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 570 TO ITERATE

100.0% PROCESSED 570 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

L11 0 SEA SSS FUL L9

=>
Uploading C:\Program Files\Stnexp\Queries\107317074.str

10731707 8/12/06



chain nodes :
6 7 8 9 10 11 12
ring nodes :
1 2 3 4 5
chain bonds :
4-6 6-7 6-8 7-11 8-9 9-10 11-12
ring bonds :
1-2 1-5 2-3 3-4 4-5
exact/norm bonds :
1-2 1-5 2-3 3-4 4-5 4-6 6-7 6-8 7-11 8-9 9-10 11-12
isolated ring systems :
containing 1 :

G1:C,N

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 8:CLASS 9:CLASS
10:CLASS 11:CLASS 12:Atom


L12 STRUCTURE UPLOADED

10731707 8/12/06

=> d

L12 HAS NO ANSWERS

L12 STR



G1 C,N

Structure attributes must be viewed using STN Express query preparation.

=> s l12

SAMPLE SEARCH INITIATED 15:24:31 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 405 TO ITERATE

100.0% PROCESSED 405 ITERATIONS

10 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 6893 TO 9307

PROJECTED ANSWERS: 11 TO 389

L13 10 SEA SSS SAM L12

=> s l12 full

FULL SEARCH INITIATED 15:24:49 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 8004 TO ITERATE

100.0% PROCESSED 8004 ITERATIONS

237 ANSWERS

SEARCH TIME: 00.00.01

L14 237 SEA SSS FUL L12

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

673.04

673.25

FILE 'CAPLUS' ENTERED AT 15:24:54 ON 18 JUL 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

10731707 8/12/06

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 18 Jul 2006 VOL 145 ISS 4
FILE LAST UPDATED: 17 Jul 2006 (20060717/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l14

L15 4 L14

=> d ibib abs histr tot

'HISTR' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'

The following are valid formats:

ABS ----- GI and AB
ALL ----- BIB, AB, IND, RE
APPS ----- AI, PRAI
BIB ----- AN, plus Bibliographic Data and PI table (default)
CAN ----- List of CA abstract numbers without answer numbers
CBIB ----- AN, plus Compressed Bibliographic Data
CLASS ----- IPC, NCL, ECLA, FTERM
DALL ----- ALL, delimited (end of each field identified)
DMAX ----- MAX, delimited for post-processing
FAM ----- AN, PI and PRAI in table, plus Patent Family data
FBIB ----- AN, BIB, plus Patent FAM
IND ----- Indexing data
IPC ----- International Patent Classifications
MAX ----- ALL, plus Patent FAM, RE
PATS ----- PI, SO
SAM ----- CC, SX, TI, ST, IT
SCAN ----- CC, SX, TI, ST, IT (random display, no answer numbers;
SCAN must be entered on the same line as the DISPLAY,
e.g., D SCAN or DISPLAY SCAN)
STD ----- BIB, CLASS

IABS ----- ABS, indented with text labels
IALL ----- ALL, indented with text labels
IBIB ----- BIB, indented with text labels
IMAX ----- MAX, indented with text labels
ISTD ----- STD, indented with text labels

OBIB ----- AN, plus Bibliographic Data (original)
OIBIB ----- OBIB, indented with text labels

SBIB ----- BIB, no citations
SIBIB ----- IBIB, no citations

HIT ----- Fields containing hit terms
 HITIND ----- IC, ICA, ICI, NCL, CC and index field (ST and IT)
 containing hit terms
 HITRN ----- HIT RN and its text modification
 HITSTR ----- HIT RN, its text modification, its CA index name, and
 its structure diagram
 HITSEQ ----- HIT RN, its text modification, its CA index name, its
 structure diagram, plus NTE and SEQ fields
 FHITSTR ----- First HIT RN, its text modification, its CA index name, and
 its structure diagram
 FHITSEQ ----- First HIT RN, its text modification, its CA index name, its
 structure diagram, plus NTE and SEQ fields
 KWIC ----- Hit term plus 20 words on either side
 OCC ----- Number of occurrence of hit term and field in which it occurs

To display a particular field or fields, enter the display field codes. For a list of the display field codes, enter HELP DFIELDS at an arrow prompt (=>). Examples of formats include: TI; TI,AU; BIB,ST; TI,IND; TI,SO. You may specify the format fields in any order and the information will be displayed in the same order as the format specification.

All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR, FHITSTR, HITSEQ, FHITSEQ, KWIC, and OCC) may be used with DISPLAY ACC to view a specified Accession Number.
 ENTER DISPLAY FORMAT (BIB):end

=> d ibib abs hitstr tot


L15 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 2002:777935 CAPLUS
 DOCUMENT NUMBER: 137:294960
 TITLE: Preparation of 3-azolypropanohydroxamic acids as
 procollagen c-proteinase (PCP) inhibitors
 INVENTOR(S): Bailey, Simon; Fish, Paul Vincent; James, Kim;
 Whitlock, Gavin Alistair
 PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.
 SOURCE: PCT Int. Appl., 209 pp.
 CODEN: PIXXD2

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002079200	A1	20021010	WO 2002-1B699	20020308
<p>W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG</p> <p>CA 2442481 AA 20021010 CA 2002-2442481 20020308 EP 1373264 A1 20040102 EP 2002-713078 20020308 EP 1373264 B1 20041222 20020308</p> <p>R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR</p> <p>BR 2002008499 A 20040420 BR 2002-8499 20020308 JP 2004524365 T2 20040812 JP 2002-577825 20020308 AT 285409 E 20050115 AT 2002-713078 20020308 ES 2232740 T3 20050601 ES 2002-2713078 20020308 US 2003069291 A1 20030410 US 2002-112338 20020329 US 6621972 B2 20041123</p>				
<p>PRIORITY APPLN. INFO.: GB 2001-8102 A 20010330 US 2001-293379P P 20010524 WO 2002-1B699 W 20020308</p>				


OTHER SOURCE(S): MARPAT 137:294960
 AB HONHCOH2CH(XR)QY (X = (fluoro-substituted) alkylene, alkenylene; R = (fluoro-substituted) aryl, cycloalkyl, cycloalkenyl; Q = oxazolyl, oxadiazolyl; Y = mono- or bicyclic unsatd. (substituted) (hetero)cyclyl], were prepared Thus, (3R)-6-cyclohexyl-3-[3-(2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)-1,2,4-oxadiazol-5-yl]hexanoic acid (preparation given) in THF was treated with Et3N, iso-Bu chloroformate, and O-trimethylsilylhydroxylamine at 0° followed by stirring at room temperature to give (3R)-6-cyclohexyl-3-[3-(2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)-1,2,4-oxadiazol-5-yl]-N-hydroxyhexanamide. Tested title compds. inhibited PCP with IC50s1 μM.
 IT 468067-00-7P 468067-01-8P 468067-02-9P
 468067-03-0P 468067-04-1P 468067-05-2P
 468067-06-3P 468067-07-4P 468067-08-5P

L15 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)




RN 468067-02-9 CAPLUS
 CN 1,2,4-Oxadiazole-5-propanamide, β-(3-cyclohexylpropyl)-N-hydroxy-3-(1-methyl-1H-imidazol-2-yl)-, (BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 468067-03-0 CAPLUS
 CN 1,2,4-Oxadiazole-5-propanamide, β-(3-cyclohexylpropyl)-3-(1,2-dihydro-6-methyl-2-oxo-3-pyridinyl)-N-hydroxy-, (BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 468067-04-1 CAPLUS
 CN 1,2,4-Oxadiazole-5-propanamide, β-(3-cyclohexylpropyl)-3-(1,6-dihydro-6-oxo-3-pyridazinyl)-N-hydroxy-, (BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L15 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)

468067-09-6P 468067-10-9P 468067-11-0P
 468067-12-1P 468067-13-2P 468067-14-3P
 468067-15-4P 468067-16-5P 468067-17-6P
 468067-19-8P 468067-20-1P 468067-21-2P
 468067-22-3P 468067-23-4P 468067-24-5P
 468067-25-6P 468067-26-7P 468067-27-8P
 468067-28-9P 468067-29-0P 468067-30-3P
 468067-31-4P 468067-32-5P 468067-33-6P
 468067-34-7P 468067-35-8P 468067-36-9P
 468067-37-0P 468067-38-1P 468067-39-2P
 468067-40-5P 468067-41-6P 468067-42-7P
 468067-43-8P 468067-44-9P 468067-45-0P
 468067-46-1P 468067-47-2P 468067-48-3P
 468067-49-4P 468067-50-7P 468067-51-8P
 468067-52-9P 468067-53-0P 468067-54-1P
 468067-55-2P 468067-56-3P 468067-57-4P
 468067-58-5P 468067-59-6P 468067-60-9P
 468067-61-0P 468067-62-1P 468067-64-3P
 468067-65-4P 468067-66-5P 468067-67-6P
 468067-68-7P 468067-69-8P 468067-70-1P
 468067-71-2P 468069-45-6P 468733-18-8P
 468733-19-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREF (Preparation); USES (Uses)
 (prepn. of 3-azolypropanohydroxamic acids as procollagen c-proteinase inhibitors)

RN 468067-00-7 CAPLUS
 CN 1,2,4-Oxadiazole-5-propanamide, β-(3-cyclohexylpropyl)-N-hydroxy-3-(1,2,3,4-tetrahydro-2,4-dioxo-5-pyrimidinyl)-, (BR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 468067-01-8 CAPLUS
 CN 1,2,4-Oxadiazole-5-propanamide, β-(3-cyclohexylpropyl)-N-hydroxy-3-(6-methyl-3-pyridazinyl)-, (BR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L15 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)




RN 468067-05-2 CAPLUS
 CN 1,2,4-Oxadiazole-5-propanamide, β-(3-cyclohexylpropyl)-N-hydroxy-3-(2-pyrimidinyl)-, (BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 468067-06-3 CAPLUS
 CN 1,2,4-Oxadiazole-5-propanamide, β-(3-cyclohexylpropyl)-N-hydroxy-3-(5-pyrimidinyl)-, (BR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 468067-07-4 CAPLUS
 CN 1,2,4-Oxadiazole-5-propanamide, β-(3-cyclohexylpropyl)-N-hydroxy-3-(3-methoxy-5-isoxazolyl)-, (BR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L15 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 468067-08-5 CAPLUS
CN 1,2,4-Oxadiazole-5-propanamide, 3-(4-amino-1,2,5-oxadiazol-3-yl)-β-(3-cyclohexylpropyl)-N-hydroxy-, (BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 468067-09-6 CAPLUS
CN 3-Pyridinecarboxylic acid, 5-[5-[(1R)-4-cyclohexyl-1-[2-(hydroxyamino)-2-oxoethyl]butyl]-1,2,4-oxadiazol-3-yl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 468067-10-9 CAPLUS
CN 3-Pyridinecarboxylic acid, 5-[5-[(1R)-4-cyclohexyl-1-[2-(hydroxyamino)-2-oxoethyl]butyl]-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L15 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 468067-14-3 CAPLUS
CN 4-Pyridinecarboxamide, 2-[5-[(1R)-4-cyclohexyl-1-[2-(hydroxyamino)-2-oxoethyl]butyl]-1,2,4-oxadiazol-3-yl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 468067-15-4 CAPLUS
CN 4-Pyridinecarboxamide, 2-[5-[(1R)-4-cyclohexyl-1-[2-(hydroxyamino)-2-oxoethyl]butyl]-1,2,4-oxadiazol-3-yl]-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 468067-16-5 CAPLUS
CN 4-Pyridinecarboxamide, 2-[5-[(1R)-4-cyclohexyl-1-[2-(hydroxyamino)-2-oxoethyl]butyl]-1,2,4-oxadiazol-3-yl]-N,N-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L15 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 468067-11-0 CAPLUS
CN 3-Pyridinecarboxamide, 5-[5-[(1R)-4-cyclohexyl-1-[2-(hydroxyamino)-2-oxoethyl]butyl]-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 468067-12-1 CAPLUS
CN 3-Pyridinecarboxamide, 5-[5-[(1R)-4-cyclohexyl-1-[2-(hydroxyamino)-2-oxoethyl]butyl]-1,2,4-oxadiazol-3-yl]-N,N-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 468067-13-2 CAPLUS
CN 3-Pyridinecarboxamide, 5-[5-[(1R)-4-cyclohexyl-1-[2-(hydroxyamino)-2-oxoethyl]butyl]-1,2,4-oxadiazol-3-yl]-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L15 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 468067-17-6 CAPLUS
CN 1,2,4-Oxadiazole-5-propanamide, β-(3-cyclohexylpropyl)-N-hydroxy-3-(2-pyridinyl)-, (BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 468067-19-8 CAPLUS
CN 1,2,4-Oxadiazole-5-propanamide, β-(3-cyclohexylpropyl)-N-hydroxy-3-(4-pyridinyl)-, (BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 468067-20-1 CAPLUS
CN 1,2,4-Oxadiazole-5-propanamide, β-(3-cyclohexylpropyl)-N-hydroxy-3-(6-methyl-3-pyridinyl)-, (BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10731707 8/12/06

L15 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 468067-21-2 CAPLUS
CN 1,2,4-Oxadiazole-5-propanamide, 3-(6-amino-3-pyridinyl)-β-(3-cyclohexylpropyl)-N-hydroxy-, (BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 468067-22-3 CAPLUS
CN 1,2,4-Oxadiazole-5-propanamide, β-(3-cyclohexylpropyl)-3-[2-(dimethylamino)-4-pyridinyl]-N-hydroxy-, (BR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 468067-23-4 CAPLUS
CN 4-Pyridinecarboxylic acid, 2-[5-[(1R)-4-cyclohexyl-1-[2-(hydroxyamino)-2-oxoethyl]butyl]-1,2,4-oxadiazol-3-yl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L15 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 468067-27-8 CAPLUS
CN 1,2,4-Oxadiazole-5-propanamide, β-(3-cyclohexylpropyl)-3-[6-(ethylamino)-3-pyridinyl]-N-hydroxy-, (BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 468067-28-9 CAPLUS
CN 1,2,4-Oxadiazole-5-propanamide, β-(3-cyclohexylpropyl)-N-hydroxy-3-[6-[(1-methylethylamino)-3-pyridinyl]-, (BR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 468067-29-0 CAPLUS
CN 1,2,4-Oxadiazole-5-propanamide, β-(3-cyclohexylpropyl)-N-hydroxy-3-[6-[(2-methoxyethylamino)-3-pyridinyl]-, (BR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L15 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 468067-24-5 CAPLUS
CN 4-Pyridinecarboxylic acid, 2-[5-[(1R)-4-cyclohexyl-1-[2-(hydroxyamino)-2-oxoethyl]butyl]-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 468067-25-6 CAPLUS
CN 2-Pyridineacetic acid, 5-[5-[(1R)-4-cyclohexyl-1-[2-(hydroxyamino)-2-oxoethyl]butyl]-1,2,4-oxadiazol-3-yl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 468067-26-7 CAPLUS
CN 1,2,4-Oxadiazole-5-propanamide, β-(3-cyclohexylpropyl)-N-hydroxy-3-[6-(methylamino)-3-pyridinyl]-, (BR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L15 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 468067-30-3 CAPLUS
CN 1,2,4-Oxadiazole-5-propanamide, β-(3-cyclohexylpropyl)-N-hydroxy-3-[6-(1-pyrrolidinyl)-3-pyridinyl]-, (BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 468067-31-4 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[5-[(1R)-4-cyclohexyl-1-[2-(hydroxyamino)-2-oxoethyl]butyl]-1,2,4-oxadiazol-3-yl]-2-pyridinyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 468067-32-5 CAPLUS
CN 1,2,4-Oxadiazole-5-propanamide, β-(3-cyclohexylpropyl)-N-hydroxy-3-[6-(1-piperazinyl)-3-pyridinyl]-, (BR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L15 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 468067-33-6 CAPLUS
CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-N-hydroxy-3-[6-(4-methyl-1-piperazinyl)-3-pyridinyl]-, (BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 468067-34-7 CAPLUS
CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-3-[6-[3-(dimethylamino)-1-azetidinyl]-3-pyridinyl]-N-hydroxy-, (BR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 468067-35-8 CAPLUS
CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-N-hydroxy-3-[6-[3-(4-morpholinyl)-1-azetidinyl]-3-pyridinyl]-, (BR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L15 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 468067-39-2 CAPLUS
CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-N-hydroxy-3-[2-(4-methyl-1-piperazinyl)-3-pyridinyl]-, (BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 468067-40-5 CAPLUS
CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-N-hydroxy-3-[2-(methylamino)-3-pyridinyl]-, (BR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 468067-41-6 CAPLUS
CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-N-hydroxy-3-pyrazinyl-, (BR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L15 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 468067-36-9 CAPLUS
CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-3-[6-(dimethylamino)-3-pyridinyl]-N-hydroxy-, (BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 468067-37-0 CAPLUS
CN 2-Pyridinecarboxylic acid, 5-[5-[(1R)-4-cyclohexyl-1-[2-(hydroxymino)-2-oxoethyl]butyl]-1,2,4-oxadiazol-3-yl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 468067-38-1 CAPLUS
CN 2-Pyridinecarboxylic acid, 5-[5-[(1R)-4-cyclohexyl-1-[2-(hydroxymino)-2-oxoethyl]butyl]-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L15 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 468067-42-7 CAPLUS
CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-N-hydroxy-3-[6-(1-pyrrolidinyl)pyrazinyl]-, (BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 468067-43-8 CAPLUS
CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-N-hydroxy-3-[6-(4-methyl-1-piperazinyl)pyrazinyl]-, (BR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 468067-44-9 CAPLUS
CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-N-hydroxy-3-[6-(1H-imidazol-1-yl)pyrazinyl]-, (BR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L15 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 468067-45-0 CAPLUS
 CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-N-hydroxy-3-[3-(4-methyl-1-piperazinyl)pyrazinyl]-, (BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 468067-46-1 CAPLUS
 CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-N-hydroxy-3-[3-(4-morpholinyl)pyrazinyl]-, (BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L15 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 468067-49-4 CAPLUS
 CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-N-hydroxy-3-[3-(methylamino)pyrazinyl]-, (BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 468067-50-7 CAPLUS
 CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-N-hydroxy-3-phenyl-, (BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 468067-51-8 CAPLUS
 CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-N-hydroxy-3-(4-methoxyphenyl)-, (BR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 468067-52-9 CAPLUS
 CN 1,2,4-Oxadiazole-5-propanamide, 3-(1,3-benzodioxol-5-yl)-beta-(3-cyclohexylpropyl)-N-hydroxy-, (BR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L15 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 468067-47-2 CAPLUS
 CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-N-hydroxy-3-[3-(1-pyrrolidinyl)pyrazinyl]-, (BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 468067-48-3 CAPLUS
 CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-3-[3-(dimethylamino)pyrazinyl]-N-hydroxy-, (BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L15 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 468067-53-0 CAPLUS
 CN Benzoic acid, 4-[5-[(1R)-4-cyclohexyl-1-[2-(hydroxyamino)-2-oxoethyl]butyl]-1,2,4-oxadiazol-3-yl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 468067-54-1 CAPLUS
 CN Benzoic acid, 4-[5-[(1R)-4-cyclohexyl-1-[2-(hydroxyamino)-2-oxoethyl]butyl]-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 468067-55-2 CAPLUS
 CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-3-[4-[(dimethylamino)sulfonyl]phenyl]-N-hydroxy-, (BR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L15 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 468067-56-3 CAPLUS
CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-N-hydroxy-3-[4-(methylsulfonyl)amino]phenyl-, (BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 468067-57-4 CAPLUS
CN Benzoic acid, 3-[5-[(1R)-4-cyclohexyl-1-[2-(hydroxyamino)-2-oxoethyl]butyl]-1,2,4-oxadiazol-3-yl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 468067-58-5 CAPLUS
CN Benzoic acid, 3-[5-[(1R)-4-cyclohexyl-1-[2-(hydroxyamino)-2-oxoethyl]butyl]-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L15 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 468067-62-1 CAPLUS
CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-3-(2-furanyl)-N-hydroxy-, (BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 468067-64-3 CAPLUS
CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-N-hydroxy-3-(3-quinoliny)-, (BR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 468067-65-4 CAPLUS
CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-N-hydroxy-3-(1-isoquinoliny)-, (BR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L15 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 468067-59-6 CAPLUS
CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-3-(3,5-dimethoxyphenyl)-N-hydroxy-, (BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 468067-60-9 CAPLUS
CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-N-hydroxy-3-(1H-pyrazol-4-yl)-, (BR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 468067-61-0 CAPLUS
CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-N-hydroxy-3-(1H-pyrazol-3-yl)-, (BR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L15 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 468067-66-5 CAPLUS
CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-N-hydroxy-3-(3-isoquinoliny)-, (BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 468067-67-6 CAPLUS
CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-N-hydroxy-3-[6-(methylsulfonyl)amino]-3-pyridiny]-, (BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 468067-68-7 CAPLUS
CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-3-(6-ethoxypyraziny)-N-hydroxy-, (BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10731707 8/12/06

L15 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 468067-69-8 CAPLUS
CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-3-[2-(1,1-dimethylethyl)-2H-tetrazol-5-yl]-N-hydroxy-, (BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 468067-70-1 CAPLUS
CN 2-Oxazolepropanamide, β -(3-cyclohexylpropyl)-N-hydroxy-5-phenyl-, (BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 468067-71-2 CAPLUS
CN 2-Oxazolepropanamide, β -(3-cyclohexylpropyl)-N-hydroxy-5-(4-pyridinyl)-, (BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L15 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
3-pyridinyl]- β -(3-cyclohexylpropyl)-N-hydroxy-, (BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 468067-18-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of 3-azolypropanohydroxamic acids as procollagen c-proteinase inhibitors)
RN 468067-18-7 CAPLUS
CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-N-hydroxy-3-(3-pyridinyl)-, (BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L15 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 468069-45-6 CAPLUS
CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-3-[1-(1,1-dimethylethyl)-1H-tetrazol-5-yl]-N-hydroxy-, (BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 468733-18-8 CAPLUS
CN Carbanic acid, [3-[5-[5-[(1R)-4-cyclohexyl-1-[2-(hydroxyamino)-2-oxoethyl]butyl]-1,2,4-oxadiazol-3-yl]-2-pyridinyl]-3-azabicyclo[3.1.0]hex-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 468733-19-9 CAPLUS
CN 1,2,4-Oxadiazole-5-propanamide, 3-[6-(6-amino-3-azabicyclo[3.1.0]hex-3-yl)-

L15 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:777913 CAPLUS
DOCUMENT NUMBER: 137:294958
TITLE: Preparation of azolyalkylhydroxamic acids as Procollagen C-Proteinase (PCP) inhibitors
INVENTOR(S): Fish, Paul Vincent; Kendall, Jackie Diane; Whitlock, Gavin Alistair
PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.
SOURCE: PCT Int. Appl., 67 pp.
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002079175	A1	20021010	WO 2002-1B817	20020318
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GR, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, HL, HR, NE, SN, TD, TG			
CA 2442483	A1	20021010	CA 2002-2442483	20020318
EP 1373231	A1	20040102	EP 2002-707045	20020318
EP 1373231	B1	20050608		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
BR 2002008500	A	20040420	BR 2002-8500	20020318
JP 2004524364	T2	20040812	JP 2002-577802	20020318
AT 297382	E	20050615	AT 2002-707045	20020318
ES 2240703	T3	20051016	ES 2002-2707045	20020318
US 2002187979	A1	20021212	US 2002-109756	20020329
US 6645993	B2	20031111		
US 2004058917	A1	20040325	US 2003-643476	20030819
US 6831088	B2	20041214		
PRIORITY APPLN. INFO.:				
			GB 2001-8097	A 20010330
			US 2001-293419P	P 20010524
			WO 2002-1B817	W 20020318
			US 2002-109756	A3 20020329

OTHER SOURCE(S): MARPAT 137:294958
GI




AB Title compds. [I: X = (fluoro-substituted) alkylene, alkenylene; R = (fluoro-substituted) aryl, cycloalkyl, cycloalkenyl; W = N, CZ; Y = alkyl (substituted) by aryl, halo; Z = H, (halo)alkyl, (substituted) aryl, carbocyclyl, heterocyclyl; with provisos], were prepared Thus,

L15 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 (3R)-6-cyclohexyl-3-[3-[[[(phenylsulfonyl)amino]carbonyl]-1,2,4-oxadiazol-5-yl]hexanoic acid (prepn. given) in THF was treated sequentially with 2,6-lutidine, iso-Bu chloroformate, and O-trimethylsilylhydroxylamine at 0° followed by stirring at room temp. overnight to give
 (3R)-6-cyclohexyl-N-hydroxy-3-[3-[[[(phenylsulfonyl)amino]carbonyl]-1,2,4-oxadiazol-5-yl]hexanamide. Tested I inhibited PCP with IC50≤100 μM.

IT 467434-08-8P 467434-09-9P 467434-10-2P
 467434-11-3P 467434-12-4P 467434-13-5P
 467434-14-6P 467434-15-7P 467434-16-8P
 467434-17-9P 467434-18-0P 467434-19-1P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of azolylalkylhydroxamic acids as Procollagen C-Proteinase (PCP) inhibitors)


RN 467434-08-8 CAPLUS
 CN 1,2,4-Oxadiazole-5-propanamide, β-(3-cyclohexylpropyl)-N-hydroxy-3-[[[(4-methoxyphenyl)sulfonyl]amino]carbonyl]-, (BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 467434-09-9 CAPLUS
 CN 1,2,4-Oxadiazole-5-propanamide, β-(3-cyclohexylpropyl)-N-hydroxy-3-[[[(4-methylphenyl)sulfonyl]amino]carbonyl]-, (BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 467434-10-2 CAPLUS

L15 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 467434-13-5 CAPLUS
 CN 1,2,4-Oxadiazole-5-propanamide, β-(3-cyclohexylpropyl)-3-[[[(3,4-dimethoxyphenyl)sulfonyl]amino]carbonyl]-N-hydroxy-, (BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 467434-14-6 CAPLUS
 CN 1,2,4-Oxadiazole-5-propanamide, β-(3-cyclohexylpropyl)-N-hydroxy-3-[[[(8-quinolinyl)sulfonyl]amino]carbonyl]-, (BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 467434-15-7 CAPLUS
 CN 1,2,4-Oxadiazole-5-propanamide, β-(3-cyclohexylpropyl)-3-[[[(3,5-dimethyl-4-isoxazolyl)sulfonyl]amino]carbonyl]-N-hydroxy-, (BR)- (9CI) (CA INDEX NAME)

Page 22 Saeed


L15 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN 1,2,4-Oxadiazole-5-propanamide, β-(3-cyclohexylpropyl)-N-hydroxy-3-[[[(4-methoxyphenyl)sulfonyl]amino]carbonyl]-, (BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 467434-11-3 CAPLUS
 CN 1,2,4-Oxadiazole-5-propanamide, β-(3-cyclohexylpropyl)-3-[[[(4-fluorophenyl)sulfonyl]amino]carbonyl]-N-hydroxy-, (BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 467434-12-4 CAPLUS
 CN 1,2,4-Oxadiazole-5-propanamide, β-(3-cyclohexylpropyl)-N-hydroxy-3-[[[(4-(1-methylethyl)phenyl)sulfonyl]amino]carbonyl]-, (BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L15 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

Absolute stereochemistry.




RN 467434-16-8 CAPLUS
 CN 1,2,4-Oxadiazole-5-propanamide, β-(3-cyclohexylpropyl)-N-hydroxy-3-[[[(1-methylethyl)sulfonyl]amino]carbonyl]-, (BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 467434-17-9 CAPLUS
 CN 1,2,4-Oxadiazole-5-propanamide, β-(3-cyclohexylpropyl)-N-hydroxy-3-[[[(methyl(methylsulfonyl)amino]carbonyl]-, (BR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 467434-18-0 CAPLUS
 CN 1,2,4-Oxadiazole-5-propanamide, β-(3-cyclohexylpropyl)-N-hydroxy-3-[[[(phenylmethyl)sulfonyl]amino]carbonyl]-, (BR)- (9CI) (CA INDEX NAME)


L15 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)

Absolute stereochemistry.



RN 467434-19-1 CAPLUS
CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-N-hydroxy-3-[[3-(pyridinylsulfonyl)amino]carbonyl]-, (BR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



L15 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS ON STN

ACCESSION NUMBER: 2002487539 CAPLUS
DOCUMENT NUMBER: 137:63245
TITLE: Preparation of 3-oxa(di)azolylopropanohydroxamic acids as procollagen c-proteinase inhibitors for treatment of wounds
INVENTOR(S): Datta, Usa; Fish, Paul Vincent; James, Kim; Whitlock, Gavin Alistair
PATENT ASSIGNER(S): Pfizer Limited, UK; Pfizer Inc.
SOURCE: PCT Int. Appl., 220 pp.
CODEN: FIKXK2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002050046	A1	20020627	WO 2001-1B2360	20011207
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2432643	AA	20020627	CA 2001-2432643	20011207
AU 2002023107	A5	20020701	AU 2002-23107	20011207
EP 1343771	A1	20030917	EP 2001-271107	20011207
EP 1343771	B1	20060412		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
BR 2001016412	A	20031230	BR 2001-16412	20011207
JP 2004521098	T2	20040715	JP 2002-551543	20011207
US 2002151535	A1	20021017	US 2001-21721	20011212
US 6716861	B2	20040406		
US 2004142986	A1	20040722	US 2003-731707	20031209
PRIORITY APPLN. INFO.:			GB 2000-31321	A 20001221
			US 2001-262355P	P 20010117
			WO 2001-1B2360	W 20011207
			US 2001-21721	A3 20011212

OTHER SOURCE(S): MARPAT 137:63245
GI

L15 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)




AB Title compds. I [wherein X = alkylene or alkenylene optionally F substituted; R = aryl cycloalkyl optionally F substituted; W = N or CZ; Y = NR1R3, or (un)substituted aminoalkyl or N-heterocyclyl; Z = H or alkyl with provision; R1 and R3 = independently H or alkyl optionally substituted by (un)substituted amino, OH, or alkoxy; and pharmaceutically acceptable salts, solvates, and prodrugs thereof] were prepared as inhibitors of procollagen C-proteinase (PCP), essential in the production of collagen.

For example, N-(cyanomethyl)methanesulfonamide was treated with aqueous hydroxylamine to give (1Z)-N'-hydroxy-2-[(methylsulfonyl)amino]ethanimidamide (87%). Addition of the glutarate (2R)-2-(2-tert-butoxy-2-oxoethyl)-5-cyclohexylpentanoate (100%), followed by cyclization in the presence of Al2O3 (50%) and deesterification (87%), afforded the 1,2,4-oxadiazol-5-ylhexanoic acid derivative. Reaction with EtOCCl and HONH2 in THF and ether provided the desired N-hydroxy-1,2,4-oxadiazol-5-ylhexanamide II' (98%). Seventy-two compds. of the invention were prepared by similar methods and inhibited PCP in a fluorogenic cleavage assay with IC50 values of 0.5 μ M or less. Preferred compds. are also selective against the matrix metalloproteinases (MMPs) MMP-1, MMP-2, MMP-9, and/or MMP-14 (no data), which play important roles in wound healing. Thus, I are useful as anticancer treatment for wounds (no data).

IT 348623-67-6P, Ethyl 2-[(1R)-1-[2-[(benzylsulfonyl)amino]-2-oxoethyl]-4-cyclohexylbutyl]-1,3-oxazole-4-carboxylate 348623-74-5P, Methyl 2-[(1R)-1-[2-[(benzylsulfonyl)amino]-2-oxoethyl]-4-cyclohexylbutyl]-5-methyl-1,3-oxazole-4-carboxylate 438630-46-7P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-[(isopropylamino)methyl]-1,3-oxazol-2-yl]hexanamide 438630-48-9P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-[(cyclopentylamino)methyl]-1,3-oxazol-2-yl]hexanamide 438630-50-3P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-[(4-morpholinylmethyl)-1,3-oxazol-2-yl]hexanamide 438630-52-5P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[5-methyl-4-[(tetrahydro-2H-pyran-4-ylamino)methyl]-1,3-oxazol-2-yl]hexanamide 438630-54-7P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[5-methyl-4-(4-morpholinylmethyl)-1,3-oxazol-2-yl]hexanamide 438631-31-3P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-1,3-oxazol-2-yl]hexanamide 438631-32-4P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-33-5P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-34-6P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-35-7P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-36-8P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-37-9P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-38-0P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-39-1P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-40-2P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-41-3P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-42-4P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-43-5P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-44-6P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-45-7P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-46-8P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-47-9P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-48-0P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-49-1P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-50-2P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-51-3P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-52-4P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-53-5P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-54-6P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-55-7P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-56-8P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-57-9P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-58-0P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-59-1P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-60-2P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-61-3P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-62-4P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-63-5P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-64-6P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-65-7P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-66-8P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-67-9P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-68-0P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-69-1P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-70-2P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-71-3P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-72-4P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-73-5P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-74-6P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-75-7P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-76-8P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-77-9P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-78-0P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-79-1P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-80-2P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-81-3P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-82-4P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-83-5P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-84-6P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-85-7P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-86-8P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-87-9P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-88-0P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-89-1P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-90-2P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-91-3P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-92-4P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-93-5P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-94-6P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-95-7P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-96-8P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-97-9P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-98-0P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-99-1P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-100-2P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-101-3P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-102-4P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-103-5P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-104-6P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-105-7P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-106-8P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-107-9P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-108-0P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-109-1P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-110-2P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-111-3P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-112-4P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-113-5P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-114-6P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-115-7P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-116-8P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-117-9P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-118-0P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-119-1P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-120-2P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-121-3P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-122-4P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-123-5P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-124-6P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-125-7P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-126-8P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-127-9P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-128-0P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-129-1P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-130-2P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-131-3P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-132-4P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-133-5P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-134-6P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-135-7P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-136-8P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-137-9P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-138-0P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-139-1P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-140-2P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-141-3P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-142-4P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-143-5P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-144-6P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-145-7P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-146-8P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-147-9P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-148-0P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-149-1P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-150-2P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-151-3P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-152-4P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-153-5P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-154-6P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-155-7P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-156-8P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-157-9P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-158-0P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-159-1P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-160-2P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-161-3P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-162-4P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-163-5P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-164-6P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-165-7P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-166-8P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-167-9P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-168-0P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-169-1P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-170-2P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-171-3P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-172-4P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-173-5P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-174-6P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-175-7P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-176-8P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-177-9P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-178-0P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-179-1P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-180-2P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl-1,3-oxazol-2-yl]hexanamide 438631-181-3P, (3R)-N-(Benzylsulfonyl)-6-cyclohexyl-3-[4-formyl-5-methyl


L15 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 438630-48-9 CAPLUS
 CN 2-Oxazolepropanamide, β -(3-cyclohexylpropyl)-4-
 {[(cyclopentylamino)methyl]-N-(phenylmethoxy)-, (BR)- (9CI) (CA INDEX NAME)}

Absolute stereochemistry.




RN 438630-50-3 CAPLUS
 CN 2-Oxazolepropanamide, β -(3-cyclohexylpropyl)-4-(4-morpholinylmethyl)-
 N-(phenylmethoxy)-, (BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 438630-52-5 CAPLUS
 CN 2-Oxazolepropanamide, β -(3-cyclohexylpropyl)-5-methyl-N-
 (phenylmethoxy)-4-[[[tetrahydro-2H-pyran-4-yl]amino]methyl]-, (BR)-
 (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 438630-54-7 CAPLUS


L15 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 (2S)-2-[5-[(1R)-4-cyclohexyl-1-[2-(hydroxyamino)-2-oxoethyl]butyl]-1,2,4-
 oxadiazol-3-yl]-1-pyrrolidinecarboxylate
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
 Preparation); THU (Therapeutic use); BIOL (Biological study); PREP
 (Preparation); RACT (Reactant or reagent); USES (Uses)
 (procollagen C-proteinase inhibitor; prepn. of
 oxa(di)azolypropanohydroxamic acid procollagen C-proteinase inhibitors
 starting from cycloaddn. of glutarates and N-hydroxycarboximidamides or
 L-serine ester)
 RN 438629-65-8 CAPLUS
 CN Carbamic acid, [5-[(1R)-4-cyclohexyl-1-[2-(hydroxyamino)-2-oxoethyl]butyl]-
 1,2,4-oxadiazol-3-yl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 438629-69-7 CAPLUS
 CN 1,2,4-Oxadiazole-5-propanamide, 3-(aminomethyl)- β -(3-
 cyclohexylpropyl)-N-hydroxy-, (BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 438630-14-9 CAPLUS
 CN 1-Pyrrolidinecarboxylic acid, 2-[5-[(1R)-4-cyclohexyl-1-[2-(hydroxyamino)-
 2-oxoethyl]butyl]-1,2,4-oxadiazol-3-yl]-, 1,1-dimethylethyl ester, (2S)-
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L15 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN 2-Oxazolepropanamide, β -(3-cyclohexylpropyl)-5-methyl-4-(4-
 morpholinylmethyl)-N-(phenylmethoxy)-, (BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 438631-31-3 CAPLUS
 CN 2-Oxazolepropanamide, β -(3-cyclohexylpropyl)-4-formyl-N-
 (phenylmethoxy)-, (BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 438631-32-4 CAPLUS
 CN 2-Oxazolepropanamide, β -(3-cyclohexylpropyl)-4-formyl-5-methyl-N-
 (phenylmethoxy)-, (BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 438629-65-3P, tert-Butyl [5-[(1R)-4-cyclohexyl-1-[2-(hydroxyamino)-
 2-oxoethyl]butyl]-1,2,4-oxadiazol-3-yl]methylcarbamate
 438629-69-7P 438630-14-9P, tert-Butyl

L15 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




IT 438629-11-9P, (3R)-6-Cyclohexyl-N-hydroxy-3-[3-
 [(methylsulfonyl)amino]methyl]-1,2,4-oxadiazol-5-yl]hexanamide
 438629-13-1P, (3R)-6-Cyclohexyl-N-hydroxy-3-[3-
 [(methylsulfonyl)amino]methyl]-1,2,4-oxadiazol-5-yl]hexanamide
 438629-15-3P, (3R)-6-Cyclohexyl-3-[3-[(methylsulfonyl)amino]methyl]-
 1,2,4-oxadiazol-5-yl]-N-hydroxyhexanamide 438629-17-5P,
 (3R)-6-Cyclohexyl-N-hydroxy-3-[3-[(isopropylsulfonyl)amino]methyl]-1,2,4-
 oxadiazol-5-yl]hexanamide 438629-19-7P, (3R)-6-Cyclohexyl-N-
 hydroxy-3-[3-[(phenylsulfonyl)amino]methyl]-1,2,4-oxadiazol-5-yl]
 hexanamide 438629-21-1P, (3R)-6-Cyclohexyl-N-hydroxy-3-[3-
 [(2-pyridinylsulfonyl)amino]methyl]-1,2,4-oxadiazol-5-yl]hexanamide
 438629-23-3P, (3R)-6-Cyclohexyl-N-hydroxy-3-[3-[(3-
 pyridinylsulfonyl)amino]methyl]-1,2,4-oxadiazol-5-yl]hexanamide
 438629-25-5P, (3R)-6-Cyclohexyl-N-hydroxy-3-[3-[(1-methyl-1H-
 imidazol-4-yl)sulfonyl]amino]methyl]-1,2,4-oxadiazol-5-yl]hexanamide
 438629-27-7P, (3R)-6-Cyclohexyl-N-hydroxy-3-[3-[(1H-pyrazol-4-
 yl)sulfonyl]amino]methyl]-1,2,4-oxadiazol-5-yl]hexanamide
 438629-29-9P, (3R)-6-Cyclohexyl-N-hydroxy-3-[3-[(4H-1,2,4-triazol-
 3-yl)sulfonyl]amino]methyl]-1,2,4-oxadiazol-5-yl]hexanamide
 438629-31-3P, (3R)-6-Cyclohexyl-3-[3-[(3,5-dimethyl-4-
 isoxazolyl)sulfonyl]amino]methyl]-1,2,4-oxadiazol-5-yl]-N-
 hydroxyhexanamide 438629-33-5P, (3R)-6-Cyclohexyl-N-hydroxy-3-[3-
 [(2-[(methylsulfonyl)amino]ethyl)-1,2,4-oxadiazol-5-yl]hexanamide
 438629-35-7P, (3R)-6-Cyclohexyl-N-hydroxy-3-[3-[(1-methylsulfonyl)-
 3-azetidinyl]-1,2,4-oxadiazol-5-yl]hexanamide 438629-37-9P,
 (3R)-6-Cyclohexyl-N-hydroxy-3-[3-[(1-methylsulfonyl)-4-piperidinyl]-1,2,4-
 oxadiazol-5-yl]hexanamide 438629-39-1P, (3R)-6-Cyclohexyl-3-[3-
 [(1,1-dioxido-2-isothiazolidinyl)methyl]-1,2,4-oxadiazol-5-yl]-N-
 hydroxyhexanamide 438629-41-5P, (3R)-3-[3-[(tert-
 butylamino)sulfonyl]amino]methyl]-1,2,4-oxadiazol-5-yl]-6-cyclohexyl-N-
 hydroxyhexanamide 438629-42-6P, (3R)-3-[3-
 [(Aminosulfonyl)amino]methyl]-1,2,4-oxadiazol-5-yl]-6-cyclohexyl-N-
 hydroxyhexanamide 438629-45-9P, (3R)-3-[3-[(Acetylaminomethyl)-
 1,2,4-oxadiazol-5-yl]-6-cyclohexyl-N-hydroxyhexanamide
 438629-47-1P, (3R)-3-[3-[(Acetylaminomethyl)-1,2,4-oxadiazol-5-yl]-
 6-cyclohexyl-N-hydroxyhexanamide 438629-49-3P,
 N-[(5-[(1R)-4-cyclohexyl-1-[2-(hydroxyamino)-2-oxoethyl]butyl]-1,2,4-
 oxadiazol-3-yl)methyl]cyclopropanecarboxamide 438629-51-7P,
 (3R)-6-Cyclohexyl-N-hydroxy-3-[3-[(methoxyacetyl)amino]methyl]-1,2,4-
 oxadiazol-5-yl]hexanamide 438629-53-9P, (3R)-6-Cyclohexyl-3-[3-
 [(dimethylamino)acetyl]amino]methyl]-1,2,4-oxadiazol-5-yl]-N-
 hydroxyhexanamide 438629-55-1P, N-[(5-[(1R)-4-cyclohexyl-1-[2-
 (hydroxyamino)-2-oxoethyl]butyl]-1,2,4-oxadiazol-3-yl)methyl]benzamide
 438629-57-3P, N-[(5-[(1R)-4-cyclohexyl-1-[2-(hydroxyamino)-2-
 oxoethyl]butyl]-1,2,4-oxadiazol-3-yl)methyl]-2-pyridinylcarboxamide
 438629-59-5P, (3R)-3-[3-[(Aminocarbonyl)amino]methyl]-1,2,4-

L15 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 oxadiazol-5-yl]-6-cyclohexyl-N-hydroxyhexanamide 438629-61-9P,
 (3R)-6-Cyclohexyl-N-hydroxy-3-[[[2-(methylamino)carbonyl]amino]methyl]-1,2,4-oxadiazol-5-yl]hexanamide 438629-63-1P,
 (3R)-6-Cyclohexyl-3-[[[2-(dimethylamino)carbonyl]amino]methyl]-1,2,4-oxadiazol-5-yl]-N-hydroxyhexanamide 438629-67-5P,
 (3R)-3-[(3-Amino-1,2,4-oxadiazol-5-yl)-6-cyclohexyl-N-hydroxyhexanamide 438629-70-0P, (3R)-6-Cyclohexyl-N-hydroxy-3-[[[2-(methylamino)carbonyl]amino]methyl]-1,2,4-oxadiazol-5-yl]hexanamide 438629-72-2P,
 (3R)-6-Cyclohexyl-3-[[[2-(methylamino)carbonyl]amino]methyl]-1,2,4-oxadiazol-5-yl]-N-hydroxyhexanamide 438629-74-4P, (3R)-6-Cyclohexyl-N-hydroxy-3-[[[2-(propylamino)carbonyl]amino]methyl]-1,2,4-oxadiazol-5-yl]hexanamide 438629-76-6P,
 (3R)-6-Cyclohexyl-N-hydroxy-3-[[[2-(isopropylamino)carbonyl]amino]methyl]-1,2,4-oxadiazol-5-yl]hexanamide 438629-78-8P, (3R)-6-Cyclohexyl-N-hydroxy-3-[[[2-(isobutylamino)carbonyl]amino]methyl]-1,2,4-oxadiazol-5-yl]hexanamide 438629-80-2P, (3R)-3-[(3-tert-Butylamino)carbonyl]amino]methyl]-1,2,4-oxadiazol-5-yl]-6-cyclohexyl-N-hydroxyhexanamide 438629-82-4P,
 (3R)-6-Cyclohexyl-3-[[[2-(1-ethylpropyl)amino]methyl]-1,2,4-oxadiazol-5-yl]-N-hydroxyhexanamide 438629-84-6P, (3R)-6-Cyclohexyl-3-[[[2-(cyclopropylamino)carbonyl]amino]methyl]-1,2,4-oxadiazol-5-yl]-N-hydroxyhexanamide 438629-86-8P, (3R)-3-[[[2-(cyclobutylamino)carbonyl]amino]methyl]-1,2,4-oxadiazol-5-yl]-6-cyclohexyl-N-hydroxyhexanamide 438629-88-0P,
 (3R)-6-Cyclohexyl-3-[[[2-(cyclopentylamino)carbonyl]amino]methyl]-1,2,4-oxadiazol-5-yl]-N-hydroxyhexanamide 438629-90-4P, (3R)-6-Cyclohexyl-3-[[[2-(cyclohexylamino)carbonyl]amino]methyl]-1,2,4-oxadiazol-5-yl]-N-hydroxyhexanamide 438629-92-6P, (3R)-6-Cyclohexyl-N-hydroxy-3-[[[2-(2-hydroxyethyl)amino]methyl]-1,2,4-oxadiazol-5-yl]hexanamide 438629-94-8P, (3R)-6-Cyclohexyl-N-hydroxy-3-[[[2-(2-hydroxy-1,1-dimethylethyl)amino]methyl]-1,2,4-oxadiazol-5-yl]hexanamide 438629-96-0P, (3R)-6-Cyclohexyl-N-hydroxy-3-[[[2-(2-methoxyethyl)amino]methyl]-1,2,4-oxadiazol-5-yl]hexanamide 438629-98-2P, (3R)-6-Cyclohexyl-N-hydroxy-3-[[[2-(3-methoxypropyl)amino]methyl]-1,2,4-oxadiazol-5-yl]hexanamide 438630-00-3P 438630-02-5P 438630-04-7P, Methyl [[5-[(1R)-4-cyclohexyl-1-[2-(hydroxyamino)-2-oxoethyl]butyl]-1,2,4-oxadiazol-3-yl]methyl]amino]acetate 438630-06-9P,
 (3R)-3-[[[2-(2-amino-2-oxoethyl)amino]methyl]-1,2,4-oxadiazol-5-yl]-6-cyclohexyl-N-hydroxyhexanamide 438630-08-1P,
 (3R)-6-Cyclohexyl-N-hydroxy-3-[[[2-(tetrahydro-2H-pyran-4-ylamino)ethyl]-1,2,4-oxadiazol-5-yl]hexanamide 438630-10-5P,
 (3R)-6-Cyclohexyl-N-hydroxy-3-[[[2-(1H-pyrazol-3-ylamino)ethyl]-1,2,4-oxadiazol-5-yl]hexanamide 438630-12-7P, (3R)-6-Cyclohexyl-3-[[[2-(1-ethyl-1H-pyrazol-5-yl)amino]methyl]-1,2,4-oxadiazol-5-yl]-N-hydroxyhexanamide 438630-16-1P, (3R)-6-Cyclohexyl-N-hydroxy-3-[[[2-(2S)-pyrrolidinyl]-1,2,4-oxadiazol-5-yl]hexanamide 438630-17-2P,
 (3R)-6-Cyclohexyl-N-hydroxy-3-[[[2-(2S)-piperidinyl]-1,2,4-oxadiazol-5-yl]hexanamide 438630-19-4P, (3R)-6-Cyclohexyl-3-[[[2-(dimethylamino)ethyl]-1,2,4-oxadiazol-5-yl]-N-hydroxyhexanamide 438630-21-8P, (3R)-6-Cyclohexyl-N-hydroxy-3-[[[2-(2-methoxyethyl)amino]methyl]-1,2,4-oxadiazol-5-yl]hexanamide 438630-23-0P, (3R)-6-Cyclohexyl-3-[[[2-(2-dimethylamino)ethyl]amino]methyl]-1,2,4-oxadiazol-5-yl]-N-hydroxyhexanamide 438630-25-2P, (3R)-3-[[[2-(2-Amino-2-oxoethyl)amino]methyl]-1,2,4-oxadiazol-5-yl]-6-cyclohexyl-N-hydroxyhexanamide 438630-27-4P, (3R)-6-Cyclohexyl-N-hydroxy-3-[[[2-(methyl[2-(methylamino)-2-oxoethyl]amino]methyl]-1,2,4-oxadiazol-5-

L15 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 yl]hexanamide 438630-29-6P, (3R)-6-Cyclohexyl-3-[[[2-(dimethylamino)-2-oxoethyl]amino]methyl]-1,2,4-oxadiazol-5-yl]-N-hydroxyhexanamide 438630-31-0P, (3R)-3-[[[2-Bis[2-methoxyethyl]amino]methyl]-1,2,4-oxadiazol-5-yl]-6-cyclohexyl-N-hydroxyhexanamide 438630-33-2P, (3R)-6-Cyclohexyl-N-hydroxy-3-[[[2-(1-pyrrolidinylmethyl)-1,2,4-oxadiazol-5-yl]hexanamide 438630-35-4P, (3R)-6-Cyclohexyl-N-hydroxy-3-[[[2-(4-hydroxy-1-piperidinylmethyl)-1,2,4-oxadiazol-5-yl]hexanamide 438630-38-7P,
 (3R)-6-Cyclohexyl-N-hydroxy-3-[[[2-(4-morpholinylmethyl)-1,2,4-oxadiazol-5-yl]hexanamide 438630-40-1P, (3R)-6-Cyclohexyl-N-hydroxy-3-[[[2-(4-methyl-1-piperazinylmethyl)-1,2,4-oxadiazol-5-yl]hexanamide 438630-43-4P, (3R)-6-Cyclohexyl-N-hydroxy-3-[[[2-(1H-1,2,4-triazol-1-ylmethyl)-1,2,4-oxadiazol-5-yl]hexanamide 438630-45-6P,
 (3R)-6-Cyclohexyl-N-hydroxy-3-[[[2-(isopropylamino)ethyl]-1,3-oxazol-2-yl]hexanamide 438630-47-8P, (3R)-6-Cyclohexyl-3-[[[2-(cyclopentylamino)ethyl]-1,3-oxazol-2-yl]-N-hydroxyhexanamide 438630-49-0P, (3R)-6-Cyclohexyl-N-hydroxy-3-[[[2-(4-morpholinylmethyl)-1,3-oxazol-2-yl]hexanamide 438630-51-4P,
 (3R)-6-Cyclohexyl-N-hydroxy-3-[[[2-(5-methyl-4-[[tetrahydro-2H-pyran-4-ylamino]methyl]-1,3-oxazol-2-yl]hexanamide 438630-53-6P,
 (3R)-6-Cyclohexyl-N-hydroxy-3-[[[2-(5-methyl-4-[[4-morpholinylmethyl]-1,3-oxazol-2-yl]hexanamide
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (procollagen c-proteinase inhibitor; prepn. of oxa(diazol)propylpropanohydroxamic acid procollagen c-proteinase inhibitors starting from cycloaddn. of glutarates and N-hydroxycarboximides or L-serine esters)
 RN 438629-11-9 CAPLUS
 CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-N-hydroxy-3-[[[2-(methylsulfonyl)amino]methyl]-, (BR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 438629-13-1 CAPLUS
 CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-N-hydroxy-3-[[[2-(methylsulfonyl)amino]methyl]-, (BR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L15 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 438629-15-3 CAPLUS
 CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-N-hydroxy-3-[[[2-(methylsulfonyl)amino]methyl]-, (BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 438629-17-5 CAPLUS
 CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-N-hydroxy-3-[[[2-(methylsulfonyl)amino]methyl]-, (BR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 438629-19-7 CAPLUS
 CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-N-hydroxy-3-[[[2-(methylsulfonyl)amino]methyl]-, (BR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L15 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 438629-21-1 CAPLUS
 CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-N-hydroxy-3-[[[2-(pyridinylsulfonyl)amino]methyl]-, (BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 438629-23-3 CAPLUS
 CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-N-hydroxy-3-[[[2-(pyridinylsulfonyl)amino]methyl]-, (BR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 438629-25-5 CAPLUS
 CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-N-hydroxy-3-[[[2-(1-methyl-1H-imidazol-4-yl)sulfonyl]amino]methyl]-, (BR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L15 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 438629-27-7 CAPLUS
 CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-N-hydroxy-3-[[[(1H-pyrazol-4-ylsulfonyl)amino]methyl]-, (BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 438629-29-9 CAPLUS
 CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-N-hydroxy-3-[[[(1H-1,2,4-triazol-3-ylsulfonyl)amino]methyl]-, (BR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 438629-31-3 CAPLUS
 CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-3-[[[(3,5-dimethyl-4-isoxazolyl)sulfonyl]amino]methyl]-N-hydroxy-, (BR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L15 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 438629-39-1 CAPLUS
 CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-3-[(1,1-dioxido-2-isothiazolidinyl)methyl]-N-hydroxy-, (BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 438629-41-5 CAPLUS
 CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-3-[[[(1,1-dimethylethyl)amino]sulfonyl]amino]methyl]-N-hydroxy-, (BR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 438629-42-6 CAPLUS
 CN 1,2,4-Oxadiazole-5-propanamide, 3-[[[amino]sulfonyl]amino]methyl]- β -(3-cyclohexylpropyl)-N-hydroxy-, (BR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L15 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 438629-33-5 CAPLUS
 CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-N-hydroxy-3-[(methylsulfonyl)amino]ethyl]-, (BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 438629-35-7 CAPLUS
 CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-N-hydroxy-3-[1-(methylsulfonyl)-3-azetidinyl]-, (BR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 438629-37-9 CAPLUS
 CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-N-hydroxy-3-[1-(methylsulfonyl)-4-piperidinyl]-, (BR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L15 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 438629-45-9 CAPLUS
 CN 1,2,4-Oxadiazole-5-propanamide, 3-[(acetylaminomethyl)- β -(3-cyclohexylpropyl)-N-hydroxy-, (BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 438629-47-1 CAPLUS
 CN 1,2,4-Oxadiazole-5-propanamide, 3-[(acetylaminomethyl)- β -(3-cyclohexylpropyl)-N-hydroxy-, (BR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 438629-49-3 CAPLUS
 CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-3-[[[cyclopropylcarbonyl]amino]methyl]-N-hydroxy-, (BR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L15 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 438629-51-7 CAPLUS
 CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-N-hydroxy-3-[[methoxyacetyl]amino]methyl-, (BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 438629-53-9 CAPLUS
 CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-3-[[dimethylamino]acetyl]amino]methyl]-N-hydroxy-, (BR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 438629-55-1 CAPLUS
 CN 1,2,4-Oxadiazole-5-propanamide, 3-[(benzoylamino)methyl]- β -(3-cyclohexylpropyl)-N-hydroxy-, (BR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L15 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 438629-63-1 CAPLUS
 CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-3-[[dimethylamino]carbonyl]amino]methyl]-N-hydroxy-, (BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 438629-67-5 CAPLUS
 CN 1,2,4-Oxadiazole-5-propanamide, 3-amino- β -(3-cyclohexylpropyl)-N-hydroxy-, (BR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 438629-70-0 CAPLUS
 CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-N-hydroxy-3-[(methylamino)methyl]-, (BR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L15 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 438629-57-3 CAPLUS
 CN 2-Pyridinecarboxamide, N-[[5-[(1R)-4-cyclohexyl-1-[2-(hydroxyamino)-2-oxoethyl]butyl]-1,2,4-oxadiazol-3-yl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 438629-59-5 CAPLUS
 CN 1,2,4-Oxadiazole-5-propanamide, 3-[[aminocarbonyl]amino]methyl]- β -(3-cyclohexylpropyl)-N-hydroxy-, (BR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 438629-61-9 CAPLUS
 CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-N-hydroxy-3-[[methylamino]carbonyl]amino]methyl]-, (BR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L15 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 438629-72-2 CAPLUS
 CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-3-[[ethylamino]methyl]-N-hydroxy-, (BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 438629-74-4 CAPLUS
 CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-N-hydroxy-3-[[propylamino]methyl]-, (BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 438629-76-6 CAPLUS
 CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-N-hydroxy-3-[[1-methylethyl]amino]methyl]-, (BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10731707 8/12/06

L15 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 438629-78-8 CAPLUS
CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-N-hydroxy-3-
[[2-methylpropyl]amino]methyl-, (BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 438629-80-2 CAPLUS
CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-3-[[1,1-
dimethylethyl]amino]methyl-N-hydroxy-, (BR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 438629-82-4 CAPLUS
CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-3-[[1-
ethylpropyl]amino]methyl-N-hydroxy-, (BR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L15 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 438629-90-4 CAPLUS
CN 1,2,4-Oxadiazole-5-propanamide, 3-[(cyclohexylamino)methyl]- β -(3-
cyclohexylpropyl)-N-hydroxy-, (BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 438629-92-6 CAPLUS
CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-N-hydroxy-3-
[[2-hydroxyethyl]amino]methyl-, (BR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 438629-94-8 CAPLUS
CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-N-hydroxy-3-
[[2-hydroxy-1,1-dimethylethyl]amino]methyl-, (BR)- (9CI) (CA INDEX
NAME)


Absolute stereochemistry.

L15 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 438629-84-6 CAPLUS
CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-3-
[(cyclopropylamino)methyl]-N-hydroxy-, (BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 438629-86-8 CAPLUS
CN 1,2,4-Oxadiazole-5-propanamide, 3-[(cyclobutylamino)methyl]- β -(3-
cyclohexylpropyl)-N-hydroxy-, (BR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 438629-88-0 CAPLUS
CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-3-
[(cyclopentylamino)methyl]-N-hydroxy-, (BR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L15 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 438629-96-0 CAPLUS
CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-N-hydroxy-3-
[[2-methoxyethyl]amino]methyl-, (BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 438629-98-2 CAPLUS
CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-N-hydroxy-3-
[[3-methoxypropyl]amino]methyl-, (BR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 438630-00-3 CAPLUS
CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-N-hydroxy-3-
[[trans-4-hydroxycyclohexyl]amino]methyl-, (BR)- (9CI) (CA INDEX
NAME)


Absolute stereochemistry.

L15 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 438630-02-5 CAPLUS
CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-N-hydroxy-3-[[trans-4-methoxycyclohexyl)amino]methyl]-, (BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 438630-04-7 CAPLUS
CN Glycine, N-[[5-[(1R)-4-cyclohexyl-1-[2-(hydroxyamino)-2-oxoethyl]butyl]-1,2,4-oxadiazol-3-yl]methyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 438630-06-9 CAPLUS
CN 1,2,4-Oxadiazole-5-propanamide, 3-[[2-amino-2-oxoethyl)amino]methyl]- β -(3-cyclohexylpropyl)-N-hydroxy-, (BR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L15 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 438630-16-1 CAPLUS
CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-N-hydroxy-3-(2S)-2-pyrrolidinyl-, (BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 438630-17-2 CAPLUS
CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-N-hydroxy-3-(2S)-2-piperidinyl-, (BR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 438630-19-4 CAPLUS
CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-3-[(dimethylamino)methyl]-N-hydroxy-, (BR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L15 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 438630-08-1 CAPLUS
CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-N-hydroxy-3-[[tetrahydro-2H-pyran-4-yl)amino]methyl]-, (BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 438630-10-5 CAPLUS
CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-N-hydroxy-3-[[1H-pyrazol-3-ylamino)methyl]-, (BR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 438630-12-7 CAPLUS
CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-3-[[1-ethyl-1H-pyrazol-5-yl)amino]methyl]-N-hydroxy-, (BR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L15 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 438630-21-8 CAPLUS
CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-N-hydroxy-3-[[2-methoxyethyl)methylamino]methyl]-, (BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 438630-23-0 CAPLUS
CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-3-[[2-(dimethylamino)ethyl)methylamino]methyl]-N-hydroxy-, (BR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 438630-25-2 CAPLUS
CN 1,2,4-Oxadiazole-5-propanamide, 3-[[2-amino-2-oxoethyl)methylamino]methyl]- β -(3-cyclohexylpropyl)-N-hydroxy-, (BR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L15 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 438630-27-4 CAPLUS
CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-N-hydroxy-3-[[methyl[2-(methylamino)-2-oxoethyl]amino]methyl]-, (BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 438630-29-6 CAPLUS
CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-3-[[[2-(dimethylamino)-2-oxoethyl]methylamino]methyl]-N-hydroxy-, (BR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 438630-31-0 CAPLUS
CN 1,2,4-Oxadiazole-5-propanamide, 3-[[bis(2-methoxyethyl)amino]methyl]- β -(3-cyclohexylpropyl)-N-hydroxy-, (BR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L15 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 438630-40-1 CAPLUS
CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-N-hydroxy-3-[(4-methyl-1-piperazinyl)methyl]-, (BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 438630-43-4 CAPLUS
CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-N-hydroxy-3-[(1H-1,2,4-triazol-1-yl)methyl]-, (BR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 438630-45-6 CAPLUS
CN 2-Oxazolepropanamide, β -(3-cyclohexylpropyl)-N-hydroxy-4-[[[1-methylethyl]amino]methyl]-, (BR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L15 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 438630-33-2 CAPLUS
CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-N-hydroxy-3-(1-pyrrolidinylmethyl)-, (BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 438630-35-4 CAPLUS
CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-N-hydroxy-3-[(4-hydroxy-1-piperidinyl)methyl]-, (BR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 438630-38-7 CAPLUS
CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-N-hydroxy-3-(4-morpholinylmethyl)-, (BR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L15 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 438630-47-8 CAPLUS
CN 2-Oxazolepropanamide, β -(3-cyclohexylpropyl)-N-hydroxy-4-[(cyclopentylamino)methyl]-, (BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 438630-49-0 CAPLUS
CN 2-Oxazolepropanamide, β -(3-cyclohexylpropyl)-N-hydroxy-4-[(4-morpholinylmethyl)-, (BR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 438630-51-4 CAPLUS
CN 2-Oxazolepropanamide, β -(3-cyclohexylpropyl)-N-hydroxy-5-methyl-4-[[[tetrahydro-2H-pyran-4-yl]amino]methyl]-, (BR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L15 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 438630-53-6 CAPLUS
CN 2-Oxazolepropanamide, β -(3-cyclohexylpropyl)-N-hydroxy-5-methyl-4-(4-morpholinylmethyl)-, (BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L15 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001489380 CAPLUS
DOCUMENT NUMBER: 135:92633
TITLE: Preparation of oxazolyl- and oxadiazolyl-containing hydroxamic acids useful as procollagen C-proteinase inhibitors
INVENTOR(S): Bailey, Simon; Billotte, Stephane; Derrick, Andrew Michael; Fish, Paul Vincent; James, Kim; Thomson, Nicholas Murray
PATENT ASSIGNEE(S): Pfizer Ltd., UK; Pfizer Inc.
SOURCE: PCT Int. Appl., 188 pp.
CODEN: FIKXU2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001047901	A1	20010705	WO 2000-1B1855	20001212
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2395186	AA	20010705	CA 2000-2395186	20001212
CA 2395186	C	20060328		
BR 2000016717	A	20020903	BR 2000-16717	20001212
EP 1240152	A1	20020918	EP 2000-981523	20001212
EP 1240152	B1	20041208		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
TR 200201642	T2	20021121	TR 2002-1642	20001212
JP 2003519133	T2	20030617	JP 2001-549373	20001212
EE 200200358	A	20031015	EE 2002-358	20001212
AT 284393	E	20041215	AT 2000-981523	20001212
ES 2231292	T3	20050516	ES 2000-981523	20001212
US 2001021718	A1	20010913	US 2000-735968	20001213
US 6448278	B2	20020910		
NO 2002003058	A	20020823	NO 2002-3058	20020624
BG 106866	A	20030331	BG 2002-106866	20020624
US 2003119807	A1	20030626	US 2002-198710	20020716
US 6897306	B2	20050524		
PRIORITY APPLN. INFO.:			GB 1999-30570	A 19991223
			US 2000-180527P	P 20000207
			WO 2000-1B1855	W 20001212
			US 2000-735968	A3 20001213

OTHER SOURCE(S): CASREACT 135:92633; MARPAT 135:92633
GI

L15 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



AB I (e.g. 5-[(1R)-4-cyclohexyl-1-[2-(hydroxyamino)-2-oxoethyl]butyl]-1,2,4-oxadiazole-3-carboxamide, shown as II) and their salts, solvates, prodrugs, etc., pharmaceutical compns. containing them, methods for their preparation, inhibition of procollagen C-proteinase (PCP) (selective against matrix metalloproteinase-1 (MMP-1) and/or MMP-2 and/or MMP-9 and/or MMP-14) and utility in treatment of conditions mediated by PCP are claimed. In I, X = C1-6 alkylene or C2-6 alkenylene, each of which is optionally substituted by ≥ 1 F atoms; R = aryl or C3-8 cycloalkyl optionally substituted by ≥ 1 F atoms; W = N or C2; Y and Z each = H, C1-4 alkyl (optionally substituted by ≥ 1 halogen, S(O)_pR₆, OR₅, CONR₁R₂, CO₂R₇ and aryl), C1-4 alkanoyl optionally substituted by ≥ 1 halogen, C1-4 alkoxy carbonyl optionally substituted by ≥ 1 halogen, or CONR₁R₂; R₁ and R₂ each = H, C3-8 cycloalkyl, C1-4 alkyl (optionally substituted by C3-8 cycloalkyl, aryl, CO₂H, CO₂R₅ and/or NR₃R₄), or R₁ and R₂ can be taken together with the N to which they are attached to represent a 4- to 6-membered heterocyclic ring optionally containing 1 or 2 further hetero atoms in the ring = N, O and S, which heterocyclic ring is optionally benzo- or pyrido-fused, and which heterocyclic ring is optionally substituted by C1-4 alkyl, CO₂H, CO₂R₅, aryl and/or NR₃R₄. R₃ and R₄ each = H, C1-4 alkyl or C1-4 alkoxy carbonyl optionally substituted by ≥ 1 halogen, or R₃ and R₄ can be taken together with the N atom to which they are attached to represent a morpholine, piperidine, azetidine or piperazine (optionally N-substituted by C1-4 alkyl) moiety; R₅ = C1-4 alkyl optionally substituted by CO₂H or CONR₃R₄; or R₅ is aryl; R₆ = C1-4 alkyl optionally substituted by ≥ 1 halogen, or aryl; R₇ = H or R₆; p = 0-2; aryl = mono- or bicyclic aromatic carbocyclic or heterocyclic system comprising 5-10 ring atoms, including up to 3 heteroatoms = N, O and S, where, if there is a N atom in the ring, it can be present as the N-oxide, which ring system is optionally substituted by ≥ 1 substituents = halogen, C1-4 alkyl optionally substituted by ≥ 1 more halogen, C1-4 alkoxy optionally substituted by ≥ 1 halogen, Ph, pyridyl, CO₂H, CONR₃R₄, CO₂(C1-4 alkyl), NR₃R₄, OH and OC(O) (C1-4 alkyl). Many of the example compds. had PCP IC₅₀ values ≤ 0.5 μ M and selectivities vs. MMP-2 > 100 -fold. Several methods of preparation are claimed and 62 example preps. are described


along with 122 examples of preps. of intermediates. For example, Et 5-[(1R)-4-cyclohexyl-1-[2-(hydroxyamino)-2-oxoethyl]butyl]-1,2,4-oxadiazole-3-carboxylate was obtained from (3R)-6-cyclohexyl-3-[(ethoxycarbonyl)-1,2,4-oxadiazol-5-yl]hexanoic acid (III) in DMF by treatment with O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate followed by reaction with NH₂OH·HCl; III was obtained from Et 5-[(1R)-1-[2-(tert-butoxy)-2-oxoethyl]-4-cyclohexylbutyl]-1,2,4-oxadiazole-3-carboxylate by thermal cyclocondensation in xylene.

IT 348623-67-6P 348623-68-7P 348623-69-8P
348623-74-5P 348623-75-6P 348623-76-7P
348623-77-8P 348624-02-2P 348624-03-3P
348624-04-4P

L15 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate) prepn. of oxazolyl- and oxadiazolyl-contg. hydroxamic acids useful as procollagen C-proteinase inhibitors for anticarring medication)
RN 348623-67-6 CAPLUS
CN 4-Oxazolecarboxylic acid, 2-[(1R)-4-cyclohexyl-1-[2-oxo-2-(phenylmethoxy)amino]ethyl]butyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 348623-68-7 CAPLUS
CN 4-Oxazolecarboxylic acid, 2-[(1R)-4-cyclohexyl-1-[2-oxo-2-(phenylmethoxy)amino]ethyl]butyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348623-69-8 CAPLUS
CN 2-Oxazolepropanamide, β -(3-cyclohexylpropyl)-4-[(dimethylamino)carbonyl]-N-(phenylmethoxy)-, (BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 348623-74-5 CAPLUS
CN 4-Oxazolecarboxylic acid, 2-[(1R)-4-cyclohexyl-1-[2-oxo-2-

10731707 8/12/06


L15 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
[(phenylmethoxy)amino]ethyl]butyl]-5-methyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 348623-75-6 CAPLUS
CN 4-Oxazolecarboxylic acid, 2-[(1R)-4-cyclohexyl-1-[2-oxo-2-[(phenylmethoxy)amino]ethyl]butyl]-5-methyl-, (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 348623-76-7 CAPLUS
CN 2-Oxazolepropanamide, beta-(3-cyclohexylpropyl)-4-[(dimethylamino)carbonyl]-5-methyl-N-(phenylmethoxy)-, (BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L15 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 348624-04-4 CAPLUS
CN Glycine, N-[[2-[(1R)-4-cyclohexyl-1-[2-oxo-2-[(phenylmethoxy)amino]ethyl]butyl]-5-methyl-4-oxazolyl]carbonyl]-, (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 348622-88-8P 348623-41-6P 348624-38-4P
348624-54-4P 348624-56-6P 348624-60-2P
348624-62-4P 348624-65-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of oxazolyl- and oxadiazolyl-containing hydroxamic acids useful as

procollagen C-proteinase inhibitors for anticancer medication)


RN 348622-88-8 CAPLUS
CN 1,2,4-Oxadiazole-5-propanamide, 3-(aminocarbonyl)-beta-(3-cyclohexylpropyl)-N-hydroxy-, (BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L15 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 348623-77-8 CAPLUS
CN 2-Oxazolepropanamide, 4-(aminocarbonyl)-beta-(3-cyclohexylpropyl)-5-methyl-N-(phenylmethoxy)-, (BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348624-02-2 CAPLUS
CN 2-Oxazolepropanamide, beta-(3-cyclohexylpropyl)-4-[[[2-(dimethylamino)ethyl]amino]carbonyl]-5-methyl-N-(phenylmethoxy)-, (BR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 348624-03-3 CAPLUS
CN Glycine, N-[[2-[(1R)-4-cyclohexyl-1-[2-oxo-2-[(phenylmethoxy)amino]ethyl]butyl]-5-methyl-4-oxazolyl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L15 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 348623-41-6 CAPLUS
CN Glycine, N-[[5-[(1R)-4-cyclohexyl-1-[2-(hydroxyamino)-2-oxoethyl]butyl]-1,2,4-oxadiazol-3-yl]carbonyl]-N-methyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 348624-38-4 CAPLUS
CN 3-Azetidinecarboxylic acid, 1-[[[5-[(1R)-4-cyclohexyl-1-[2-(hydroxyamino)-2-oxoethyl]butyl]-1,2,4-oxadiazol-3-yl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 348624-54-4 CAPLUS
CN 1-Azetidinecarboxylic acid, 3-[[[5-[(1R)-4-cyclohexyl-1-[2-(hydroxyamino)-2-oxoethyl]butyl]-1,2,4-oxadiazol-3-yl]carbonyl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L15 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
Absolute stereochemistry.




RN 348624-56-6 CAPLUS
CN Imidodicarbonic acid, [1-[[5-[(1R)-4-cyclohexyl-1-[2-(hydroxylamino)-2-oxoethyl]butyl]-1,2,4-oxadiazol-3-yl]carbonyl]-3-azetidinyl]-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 348624-60-2 CAPLUS
CN Acetic acid, [[5-[(1R)-4-cyclohexyl-1-[2-(hydroxylamino)-2-oxoethyl]butyl]-1,2,4-oxadiazol-3-yl]methoxy]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L15 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of oxazolyl- and oxadiazolyl-contg. hydroxamic acids useful as procollagen C-proteinase inhibitors for anticarcinogenic medication)
RN 348622-89-9 CAPLUS
CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-N-hydroxy-3-[(methylamino)carbonyl]-, (BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 348622-90-2 CAPLUS
CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-3-[(dimethylamino)carbonyl]-N-hydroxy-, (BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348624-24-8 CAPLUS
CN 1,2,4-Oxadiazole-3-carboxylic acid, 5-[(1R)-4-cyclohexyl-1-[2-(hydroxylamino)-2-oxoethyl]butyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 348624-25-9 CAPLUS
CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-N-hydroxy-3-


L15 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 348624-62-4 CAPLUS
CN Propanoic acid, 2-[[5-[(1R)-4-cyclohexyl-1-[2-(hydroxylamino)-2-oxoethyl]butyl]-1,2,4-oxadiazol-3-yl]methoxy]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348624-65-7 CAPLUS
CN 1,2,4-Oxadiazole-3-propanoic acid, 5-[(1R)-4-cyclohexyl-1-[2-(hydroxylamino)-2-oxoethyl]butyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 348622-89-9P 348622-90-2P 348624-24-8P
348624-25-9P 348624-26-0P 348624-27-1P
348624-28-2P 348624-29-3P 348624-30-6P
348624-31-7P 348624-32-8P 348624-33-9P
348624-34-0P 348624-35-1P 348624-36-2P
348624-37-3P 348624-39-5P 348624-40-8P
348624-41-9P 348624-42-0P 348624-43-1P
348624-44-2P 348624-45-3P 348624-46-4P
348624-47-5P 348624-48-6P 348624-49-7P
348624-50-0P 348624-51-1P 348624-52-2P
348624-53-3P 348624-55-5P 348624-57-7P
348624-58-8P 348624-59-9P 348624-61-3P
348624-63-5P 348624-64-6P 348624-66-8P
348624-67-9P 348624-68-0P 348624-69-1P
348624-70-4P 348624-71-5P 348624-72-6P
348624-73-7P 348624-74-8P 348624-75-9P
348624-76-0P 348624-77-1P 348624-78-2P
348624-79-3P 348624-80-6P 348624-81-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);


L15 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
[[propylamino)carbonyl]-, (BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 348624-26-0 CAPLUS
CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-N-hydroxy-3-[[[(1-methyl)ethyl]amino]carbonyl]-, (BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348624-27-1 CAPLUS
CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-3-[[[(cyclopropylmethyl)amino]carbonyl]-N-hydroxy-, (BR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 348624-28-2 CAPLUS
CN 1,2,4-Oxadiazole-5-propanamide, 3-[(cyclobutylamino)carbonyl]- β -(3-cyclohexylpropyl)-N-hydroxy-, (BR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L15 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 348624-29-3 CAPLUS
CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-N-hydroxy-3-[[[2-methoxyphenyl]methyl]amino]carbonyl-, (BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348624-30-6 CAPLUS
CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-N-hydroxy-3-[[[4-methoxyphenyl]methyl]amino]carbonyl-, (BR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 348624-31-7 CAPLUS
CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-N-hydroxy-3-[[[2-pyridinylmethyl]amino]carbonyl-, (BR)- (9CI) (CA INDEX NAME)


L15 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

Absolute stereochemistry.



RN 348624-35-1 CAPLUS
CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-N-hydroxy-3-[[[4-(4-pyridinyl)-1-piperidinyl]carbonyl]-, (BR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 348624-36-2 CAPLUS
CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-N-hydroxy-3-[[[methyl(2-pyridinylmethyl)amino]carbonyl]-, (BR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L15 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 348624-32-8 CAPLUS
CN Glycine, N-[[[5-[(1R)-4-cyclohexyl-1-[2-(hydroxyamino)-2-oxoethyl]butyl]-1,2,4-oxadiazol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 348624-33-9 CAPLUS
CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-3-[[[4-(dimethylamino)-1-piperidinyl]carbonyl]-N-hydroxy-, (BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 348624-34-0 CAPLUS
CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-N-hydroxy-3-[[[3-(4-morpholinyl)-1-azetidinyl]carbonyl]-, (BR)- (9CI) (CA INDEX NAME)

L15 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 348624-37-3 CAPLUS
CN Glycine, N-[[[5-[(1R)-4-cyclohexyl-1-[2-(hydroxyamino)-2-oxoethyl]butyl]-1,2,4-oxadiazol-3-yl]carbonyl]-N-methyl-, (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348624-39-5 CAPLUS
CN 3-Azetidinocarboxylic acid, 1-[[[5-[(1R)-4-cyclohexyl-1-[2-(hydroxyamino)-2-oxoethyl]butyl]-1,2,4-oxadiazol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 348624-40-8 CAPLUS
CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-N-hydroxy-3-methyl-, (BR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L15 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 348624-41-9 CAPLUS
 CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-N-hydroxy-3-(1-methylethyl)-, (BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348624-42-0 CAPLUS
 CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-N-hydroxy-3-(methoxymethyl)-, (BR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 348624-43-1 CAPLUS
 CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-N-hydroxy-3-(2-methoxyethyl)-, (BR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L15 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 348624-47-5 CAPLUS
 CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-N-hydroxy-3-(2-pyridinylmethyl)-, (BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348624-48-6 CAPLUS
 CN 4-Oxazolecarboxylic acid, 2-[(1R)-4-cyclohexyl-1-[2-(hydroxyamino)-2-oxoethyl]butyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 348624-49-7 CAPLUS
 CN 2-Oxazolepropanamide, β -(3-cyclohexylpropyl)-4-[(dimethylamino)carbonyl]-N-hydroxy-, (BR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L15 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 348624-44-2 CAPLUS
 CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-N-hydroxy-3-[2-oxo-2-(1-pyrrolidinyl)ethyl]-, (BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348624-45-3 CAPLUS
 CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-N-hydroxy-3-[(phenylsulfonyl)methyl]-, (BR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 348624-46-4 CAPLUS
 CN 1,2,4-Oxadiazole-5-propanamide, 3-[(4-chlorophenoxy)methyl]-beta-(3-cyclohexylpropyl)-N-hydroxy-, (BR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L15 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 348624-50-0 CAPLUS
 CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-N-hydroxy-3-(1-pyrrolidinylcarbonyl)-, (BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348624-51-1 CAPLUS
 CN 2-Oxazolepropanamide, β -(3-cyclohexylpropyl)-4-[(dimethylamino)carbonyl]-N-hydroxy-5-methyl-, (BR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 348624-52-2 CAPLUS
 CN 2-Oxazolepropanamide, 4-(aminocarbonyl)-beta-(3-cyclohexylpropyl)-N-hydroxy-5-methyl-, (BR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L15 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 348624-53-3 CAPLUS
 CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-3-[[3-(dimethylamino)-1-azetidiny]carbonyl]-N-hydroxy-, (BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348624-55-5 CAPLUS
 CN 1,2,4-Oxadiazole-5-propanamide, 3-[[3-azetidinylamino]carbonyl]- β -(3-cyclohexylpropyl)-N-hydroxy-, (BR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 348624-57-7 CAPLUS
 CN 1,2,4-Oxadiazole-5-propanamide, 3-[[3-amino-1-azetidiny]carbonyl]- β -(3-cyclohexylpropyl)-N-hydroxy-, (BR)- (9CI) (CA INDEX NAME)


L15 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN Acetic acid, [[5-[[1R]-4-cyclohexyl-1-[2-(hydroxyamino)-2-oxoethyl]butyl]-1,2,4-oxadiazol-3-yl]methoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 348624-63-5 CAPLUS
 CN Propanoic acid, 2-[[5-[[1R]-4-cyclohexyl-1-[2-(hydroxyamino)-2-oxoethyl]butyl]-1,2,4-oxadiazol-3-yl]methoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348624-64-6 CAPLUS
 CN 1,2,4-Oxadiazole-5-propanamide, 3-[[2-amino-2-oxoethyl]methyl]- β -(3-cyclohexylpropyl)-N-hydroxy-, (BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 348624-66-8 CAPLUS
 CN 1,2,4-Oxadiazole-3-propanoic acid, 5-[[1R]-4-cyclohexyl-1-[2-(hydroxyamino)-2-oxoethyl]butyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L15 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

Absolute stereochemistry.




RN 348624-58-8 CAPLUS
 CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-3-[[[2-(dimethylamino)ethyl]methylamino]carbonyl]-N-hydroxy-, (BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 348624-59-9 CAPLUS
 CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-3-[[[2-(dimethylamino)propyl]methylamino]carbonyl]-N-hydroxy-, (BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 348624-61-3 CAPLUS

L15 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 348624-67-9 CAPLUS
 CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-N-hydroxy-3-[(propylsulfonyl)methyl]-, (BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348624-68-0 CAPLUS
 CN 2-Oxazolepropanamide, β -(3-cyclohexylpropyl)-4-[[[2-(dimethylamino)ethyl]amino]carbonyl]-N-hydroxy-5-methyl-, (BR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 348624-69-1 CAPLUS
 CN Glycine, N-[[2-[[1R]-4-cyclohexyl-1-[2-(hydroxyamino)-2-oxoethyl]butyl]-5-methyl-4-oxazolyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L15 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 348624-70-4 CAPLUS
CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-N-hydroxy-3-(1H-imidazol-2-ylmethyl)-, (BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348624-71-5 CAPLUS
CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-N-hydroxy-3-(4-pyridinylmethyl)-, (BR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 348624-72-6 CAPLUS
CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-N-hydroxy-3-(3-pyridinylmethyl)-, (BR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L15 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 348624-76-0 CAPLUS
CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-3-[(1,3-dihydro-2H-isindol-2-yl)carbonyl]-N-hydroxy-, (BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348624-77-1 CAPLUS
CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-3-[(3,4-dihydro-2(1H)-isoquinolinyl)carbonyl]-N-hydroxy-, (BR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 348624-78-2 CAPLUS
CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-N-hydroxy-3-(4-morpholinylcarbonyl)-, (BR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L15 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 348624-73-7 CAPLUS
CN 2-Oxazolepropanamide, β -(3-cyclobutylpropyl)-4-[(dimethylamino)carbonyl]-N-hydroxy-, (BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348624-74-8 CAPLUS
CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-N-hydroxy-3-[(phenylmethyl)amino]carbonyl-, (BR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 348624-75-9 CAPLUS
CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-N-hydroxy-3-(1-piperidinylcarbonyl)-, (BR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L15 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 348624-79-3 CAPLUS
CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-N-hydroxy-3-[(4-methyl-1-piperazinyl)carbonyl]-, (BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348624-80-6 CAPLUS
CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-3-[(7,8-dihydro-1,6-naphthyridin-6(5H)-yl)carbonyl]-N-hydroxy-, (BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348624-81-7 CAPLUS
CN 1,2,4-Oxadiazole-5-propanamide, β -(3-cyclohexylpropyl)-N-hydroxy-3-[(methyl(phenylmethyl)amino)carbonyl]-, (BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.